These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11155152)

  • 1. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update.
    Thévenot T; Regimbeau C; Ratziu V; Leroy V; Opolon P; Poynard T
    J Viral Hepat; 2001 Jan; 8(1):48-62. PubMed ID: 11155152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
    Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
    Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon for interferon naive patients with chronic hepatitis C.
    Myers RP; Regimbeau C; Thevenot T; Leroy V; Mathurin P; Opolon P; Zarski JP; Poynard T
    Cochrane Database Syst Rev; 2002; 2002(2):CD000370. PubMed ID: 12076394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group.
    Chemello L; Cavalletto L; Bernardinello E; Boccato S; Casarin P; Cavinato F; Urban F; Pontisso P; Cecchetto A; Gatta A; Alberti A
    J Viral Hepat; 1999 Jul; 6(4):321-7. PubMed ID: 10607247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment.
    Gürsoy M; Gür G; Arslan H; Ozdemir N; Boyacioglu S
    J Viral Hepat; 2001 Jan; 8(1):70-7. PubMed ID: 11155154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained virological response in chronic hepatitis C patients after a 6- and a 36-month interferon-alpha2b treatment schedule: a multicenter, randomized, controlled study.
    Damen M; Weegink CJ; Mauser-Bunschoten EP; Cuypers HT; Hermus MC; Sillekens P; Haan E; van den Berg HM; Bresters D; Lelie PN; Chamuleau RA; Reesink HW
    Scand J Gastroenterol; 2001 Jan; 36(1):97-104. PubMed ID: 11218246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
    Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon for acute hepatitis C.
    Poynard T; Regimbeau C; Myers RP; Thevenot T; Leroy V; Mathurin P; Opolon P; Zarski JP
    Cochrane Database Syst Rev; 2002; 2001(1):CD000369. PubMed ID: 11869573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration.
    Poynard T; Leroy V; Cohard M; Thevenot T; Mathurin P; Opolon P; Zarski JP
    Hepatology; 1996 Oct; 24(4):778-89. PubMed ID: 8855176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy.
    Angelico M; Cepparulo M; Angelico F; Francioso S; Barlattani A; Di Candilo F; Della Vecchia R; Demelia L; De Sanctis G; Gentile S; Grieco A; Parruti G; Sabusco G; Tarquini L; Tosti A; Zaru S;
    Aliment Pharmacol Ther; 2004 Feb; 19(3):339-47. PubMed ID: 14984381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
    Shepherd J; Waugh N; Hewitson P
    Health Technol Assess; 2000; 4(33):1-67. PubMed ID: 11134916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
    Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
    J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha interferon treatment in chronic hepatitis C.
    Idéo G; Bellobuono A; Mondazzi L; Tempini S; Bellati G; Idéo GM; Silini E
    Clin Exp Rheumatol; 1995; 13 Suppl 13():S167-73. PubMed ID: 8730501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural interferon alpha treatment and interferon alpha receptor 2 levels in acute hepatitis C.
    Ohata K; Yano K; Yatsuhashi H; Daikoku M; Koga M; Eguchi K; Yano M
    Dig Dis Sci; 2004 Feb; 49(2):289-94. PubMed ID: 15104372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
    Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
    J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. Tokyo-Chiba Hepatitis Research Group.
    Shiratori Y; Moriyama M; Imazeki F; Ohkubo H; Tanaka N; Arakawa Y; Yoshida H; Yokosuka O; Shibuya A; Matsuzaki K; Hashimoto E; Hayashi N; Hirata K; Ohashi Y; Omata M
    Liver; 2000 Jul; 20(4):271-80. PubMed ID: 10959805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.